Lindsay C. Burrage

Lindsay C. Burrage

Auto-generated profile, based on publicly available information

Lindsay C. Burrage

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DMDavid R. Murdock
David R. Murdock
HDHongzheng Dai
Hongzheng Dai
LBLindsay C. Burrage
Lindsay C. Burrage
JRJill A. Rosenfeld
Jill A. Rosenfeld
SKShamika Ketkar
Shamika Ketkar
BLBrendan Lee
Brendan Lee
BACKGROUND. Transcriptome sequencing (RNA-seq) improves diagnostic rates in individuals with suspected Mendelian conditions to varying degrees, primarily by directing the prioritization of candidate DNA variants identified on exome or genome sequencing (ES/GS). Here we implemented an RNA-seq–guided method to diagnose individuals across a wide range of ages and clinical phenotypes. METHODS. One hundred fifteen undiagnosed adult and pediatric patients with diverse phenotypes and 67 family members (182 total individuals) underwent RNA-seq from whole blood and skin fibroblasts at the Baylor College of Medicine (BCM) Undiagnosed Diseases Network clinical site from 2014 to 2020. We implemented a workflow to detect outliers in gene expression and splicing for cases that remained undiagnosed despite standard genomic and transcriptomic analysis. RESULTS. The transcriptome-directed approach resulted in a diagnostic rate of 12% across the entire cohort, or 17% after excluding cases solved on ES/GS alone. Newly diagnosed conditions included Koolen–de Vries syndrome (KANSL1), Renpenning syndrome (PQBP1), TBCK-associated encephalopathy, NSD2- and CLTC-related intellectual disability, and others, all with negative conventional genomic testing, including ES and chromosomal microarray (CMA). Skin fibroblasts exhibited higher and more consistent expression of clinically relevant genes than whole blood. In solved cases with RNA-seq from both tissues, the causative defect was missed in blood in half the cases but none from fibroblasts. CONCLUSIONS. For our cohort of undiagnosed individuals with suspected Mendelian conditions, transcriptome-directed genomic analysis facilitated diagnoses, primarily through the identification of variants missed on ES and CMA. TRIAL REGISTRATION. Not applicable. FUNDING. NIH Common Fund, BCM Intellectual and Developmental Disabilities Research Center, Eunice Kennedy Shriver National Institute of Child Health & Human Development.

1 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ZJZixue Jin
Zixue Jin
JKJordan Kho
Jordan Kho
BDBrian Dawson
Brian Dawson
MJMing-Ming Jiang
Ming-Ming Jiang
YCYuqing Chen
Yuqing Chen
BLBrendan Lee
Brendan Lee
Previous studies have shown that nitric oxide (NO) supplements may prevent bone loss and fractures in preclinical models of estrogen deficiency. However, the mechanisms by which NO modulates bone anabolism remain largely unclear. Argininosuccinate lyase (ASL) is the only mammalian enzyme capable of synthesizing arginine, the sole precursor for nitric oxide synthase–dependent (NOS-dependent) NO synthesis. Moreover, ASL is also required for channeling extracellular arginine to NOS for NO production. ASL deficiency (ASLD) is thus a model to study cell-autonomous, NOS-dependent NO deficiency. Here, we report that loss of ASL led to decreased NO production and impairment of osteoblast differentiation. Mechanistically, the bone phenotype was at least in part driven by the loss of NO-mediated activation of the glycolysis pathway in osteoblasts that led to decreased osteoblast differentiation and function. Heterozygous deletion of caveolin 1, a negative regulator of NO synthesis, restored NO production, osteoblast differentiation, glycolysis, and bone mass in a hypomorphic mouse model of ASLD. The translational significance of these preclinical studies was further reiterated by studies conducted in induced pluripotent stem cells from an individual with ASLD. Taken together, our findings suggest that ASLD is a unique genetic model for studying NO-dependent osteoblast function and that the NO/glycolysis pathway may be a new target to modulate bone anabolism.


1 September 2012 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
LBLindsay C. Burrage
Lindsay C. Burrage
JMJudy McConnell
Judy McConnell
RHRebecca Haesler
Rebecca Haesler
MOMary Ann O'Riordan
Mary Ann O'Riordan
VSV. Reid Sutton
V. Reid Sutton
SMShawn E. McCandless
Shawn E. McCandless

23 January 2019 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
LBLindsay C. Burrage
Lindsay C. Burrage
LTLillian Thistlethwaite
Lillian Thistlethwaite
BSBridget M. Stroup
Bridget M. Stroup
QSQin Sun
Qin Sun
MMMarcus J. Miller
Marcus J. Miller
SESarah H. Elsea
Sarah H. Elsea
Purpose Untargeted metabolomic analysis is increasingly being used in the screening and management of individuals with inborn errors of metabolism (IEM). We aimed to test whether untargeted metabolomic analysis in plasma might be useful for monitoring the disease course and management of urea cycle disorders (UCDs). Methods Untargeted mass spectrometry–based metabolomic analysis was used to generate z-scores for more than 900 metabolites in plasma from 48 individuals with various UCDs. Pathway analysis was used to identify common pathways that were perturbed in each UCD. Results Our metabolomic analysis in plasma identified multiple potentially neurotoxic metabolites of arginine in arginase deficiency and, thus, may have utility in monitoring the efficacy of treatment in arginase deficiency. In addition, we were also able to detect multiple biochemical perturbations in all UCDs that likely reflect clinical management, including metabolite alterations secondary to dietary and medication management. Conclusion In addition to utility in screening for IEM, our results suggest that untargeted metabolomic analysis in plasma may be beneficial for monitoring efficacy of clinical management and off-target effects of medications in UCDs and potentially other IEM.

1 December 2019 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
NPNishitha R. Pillai
Nishitha R. Pillai
BSBridget M. Stroup
Bridget M. Stroup
APAnna Poliner
Anna Poliner
LRLinda Rossetti
Linda Rossetti
BRBrandy Rawls
Brandy Rawls
LBLindsay C. Burrage
Lindsay C. Burrage